Saturday, July 12, 2025

Latest

Cresco Labs Posts 1.8% Sequential Revenue Growth In Second Quarter

Cresco Labs (CSE: CL) was the latest cannabis operator to report earnings this morning for the second quarter. Growth has slowed for the company, whom only saw 1.8% growth on a sequential basis, and 4% growth on a year over year basis.

Recognizing the growth story is aging quickly, CEO Charles Bachtell commented within the release, “Over the next three years, growth will come from the transition to adult use in seven large markets: New Jersey, New York, Pennsylvania, Ohio, Virginia, Florida and Maryland. Our combined footprint with Columbia Care, gives us exposure to all of these markets and leading positions in several. This is arguably the highest value footprint in cannabis – 180 million Americans and all 10 of the 10 highest projected 2025 revenue states.”

Revenue for the quarter amounted to $218.2 million, versus $214.4 million in the first quarter. Margins however improved slightly, climbing from 50.1% to that of 51.7% on a sequential basis.

Operating expenses meanwhile climbed to $90.1 million, lead by SG&A of $77.9 million. Income from operations as a result totaled $22.7 million.

After other expenses of $7.3 million and income tax expenses of $23.6 million, the firm reported a net loss of $8.3 million for the quarter, versus a loss of $23.7 million in the first quarter. Adjusted EBITDA declined slightly on a sequential basis, falling from $50.7 million to $50.6 million in the second quarter.

The major item for the second quarter appears to be the firms cash position, which fell substantially from $179.3 million to $89.5 million. Total current assets meanwhile dropped from $399.8 million to that of $314.3 million over the three month period, while total liabilities fell from $331.2 million to that of $228.2 million.

In terms of the acquisition of Columbia Care (CSE: CCHW), the company expects the transaction to clear “around year-end.” Divestiture and regulatory processes are reportedly on track at this point in time for the transaction to proceed, with Columbia Care shareholders approving the transaction in July. Court approval was granted several days later.

Cresco Labs last traded at $4.81 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Cresco Labs: Canaccord, Eight Capital Raise Price Targets

Cresco Labs (CSE: CL) reported its second-quarter 2020 financials yesterday, posting revenue growth of 42%...

Friday, August 21, 2020, 04:03:00 PM

Haywood Drops Cresco Labs Price Target To $24.50

Cresco Labs (CSE: CL) reported its first-quarter financial results this past week. The company announced...

Monday, May 31, 2021, 11:40:00 AM

Cresco Labs To Acquire Pennsylvania Operator Laurel Harvest For US$80 Million

Cresco Labs (CSE: CL) reported on Thursday the execution of an agreement to acquire 100%...

Friday, October 15, 2021, 10:56:00 AM

Cowen & Co Issues US Cannabis Update, Remains Bullish on Green Thumb, Cresco, Curaleaf

On the first of the month, Cowen and Co sent out an industry update specifically...

Sunday, September 6, 2020, 01:37:00 PM

Former Cresco Labs Director Unloads $6.2 Million In Shares Over Two Weeks

Evidently, the reason someone steps down from their role as a director of a cannabis...

Monday, July 26, 2021, 08:56:05 PM